AbCellera Presents Phase 2 Data for ABCL635
VANCOUVER, British Columbia — September 16, 2026 AbCellera announced that it will present Phase 2 efficacy and safety data...
Biotechnology
Advertisement
Acurx Pharmaceuticals Presents Ibezapolstat C. difficile Data
New York, New York, September 15, 2026 Acurx Pharmaceuticals has announced the presentation of new preclinical microbiology data for...
QurCan Therapeutics and Lilly Advance Nucleic Acid Therapies
Cambridge, Massachusetts, September 15, 2026 QurCan Therapeutics has entered into a strategic research and collaboration agreement with Eli Lilly...
Evaxion Expands AI-Immunology Platform Into Autoimmune Disease
COPENHAGEN, Denmark — September 14, 2026 Evaxion A/S announced that it has begun applying its proprietary AI-Immunology™ platform to...
Agomab Advances AGMB-447 Into Phase 2 for IPF
ANTWERP, Belgium — September 14, 2026 Agomab Therapeutics NV announced positive Phase 1 results for AGMB-447, an investigational inhaled,...
Advertisements
GSK’s Ris-Rez Cuts Death Risk in Relapsed SCLC
London, United Kingdom, September 13, 2026 GSK has announced positive Phase III ARTEMIS-008 results showing that its investigational risvutatug...
Eloxx Begins Phase 2b Study of Exaluren in Alport Syndrome
Arlington, Massachusetts, U.S., September 11, 2026 Eloxx Pharmaceuticals has announced that the first two patients have been dosed in...
Lundbeck Gains FDA Orphan Drug Status for Asedebart
Copenhagen, Denmark, September 10, 2026 H. Lundbeck A/S has announced that the U.S. Food and Drug Administration (FDA) has...
Avance Clinical Wins Australia-Taiwan Business Award
Taipei, Taiwan, September 11, 2026 Avance Clinical has received the Australia-Taiwan Business Excellence Award from the Australia New Zealand...
Cardiol Therapeutics Files US$150M Shelf Prospectus
Toronto, Ontario, Canada, September 10, 2026 Cardiol Therapeutics Inc. has filed a US$150 million preliminary short form base shelf...
Advertisement
